Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Thrombopoietin receptor agonists: ten years later.

Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB.

Haematologica. 2019 Jun;104(6):1112-1123. doi: 10.3324/haematol.2018.212845. Epub 2019 May 9. Review.

2.

Maternal sensitization occurs before delivery in severe cases of fetal alloimmune thrombocytopenia.

Jin JC, Lakkaraja MM, Ferd P, Manotas K, Gabor J, Wissert M, Berkowitz RL, McFarland JG, Bussel JB.

Am J Hematol. 2019 May 6. doi: 10.1002/ajh.25503. [Epub ahead of print] No abstract available.

PMID:
31056760
3.

Response to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia.

Hogan M, Geyer JT, Bussel JB.

Am J Hematol. 2019 Jul;94(7):E196-E198. doi: 10.1002/ajh.25496. Epub 2019 May 3. No abstract available.

PMID:
31012979
4.

Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.

Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM.

Am J Hematol. 2019 Jul;94(7):741-750. doi: 10.1002/ajh.25479. Epub 2019 Apr 29.

PMID:
30945320
5.

Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists.

Garabet L, Ghanima W, Rangberg A, Teruel-Montoya R, Martinez C, Lozano ML, Nystrand CF, Bussel JB, Sandset PM, Jonassen CM.

Platelets. 2019 Mar 18:1-8. doi: 10.1080/09537104.2019.1585527. [Epub ahead of print]

PMID:
30885035
6.

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.

Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, Raj A, Carpenter N, Mehta B, Eisen M.

Haematologica. 2019 Mar 7. pii: haematol.2018.202283. doi: 10.3324/haematol.2018.202283. [Epub ahead of print]

7.

Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.

Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, Tong S, Duliege AM.

Am J Hematol. 2019 May;94(5):546-553. doi: 10.1002/ajh.25444. Epub 2019 Mar 13.

PMID:
30784097
8.

Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.

Grainger JD, Blanchette VS, Grotzinger KM, Roy A, Bussel JB.

Br J Haematol. 2019 Apr;185(1):102-106. doi: 10.1111/bjh.15732. Epub 2018 Dec 27.

PMID:
30592022
9.

Health-related quality of life in adult primary immune thrombocytopenia.

Sestøl HG, Trangbæk SM, Bussel JB, Frederiksen H.

Expert Rev Hematol. 2018 Nov 16:1-11. doi: 10.1080/17474086.2018.1548930. [Epub ahead of print]

PMID:
30444433
10.

Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.

Khelif A, Saleh MN, Salama A, Portella MDSO, Duh MS, Ivanova J, Grotzinger K, Roy AN, Bussel JB.

Am J Hematol. 2019 Feb;94(2):200-208. doi: 10.1002/ajh.25348. Epub 2018 Nov 29.

PMID:
30417939
11.

Integrating Healthy Eating into Evidence-Based Home Visiting Models: An Analysis of Programs and Opportunities for Dietetic Practice.

Welker EB, Lott MM, Sundermann JL, Bussel JB, Story MT.

J Acad Nutr Diet. 2018 Nov 8. pii: S2212-2672(18)30866-9. doi: 10.1016/j.jand.2018.08.167. [Epub ahead of print] No abstract available.

PMID:
30415895
12.

Avatrombopag.

Bussel JB.

Br J Haematol. 2018 Nov;183(3):342-343. doi: 10.1111/bjh.15568. Epub 2018 Oct 23. No abstract available.

PMID:
30351482
13.

Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.

Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B.

Sci Transl Med. 2018 Sep 12;10(458). pii: eaas9563. doi: 10.1126/scitranslmed.aas9563.

PMID:
30209246
14.

IVIg and FcγRIIb in kids with ITP: individualizing therapy.

Despotovic JM, Bussel JB.

Blood. 2018 Aug 30;132(9):877-878. doi: 10.1182/blood-2018-07-861690. No abstract available.

PMID:
30166359
15.

Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists.

Guitton Z, Terriou L, Lega JC, Nove-Josserand R, Hie M, Amoura Z, Bussel JB, Hamidou M, Rosenthal E, Lioger B, Chauveau D, Chaminade A, Magy-Bertrand N, Michel M, Audia S, Godeau B, Mahevas M.

Rheumatology (Oxford). 2018 Aug 1;57(8):1432-1438. doi: 10.1093/rheumatology/key119.

PMID:
29757439
16.

Screening for Wiskott-Aldrich syndrome by flow cytometry.

Chiang SCC, Vergamini SM, Husami A, Neumeier L, Quinn K, Ellerhorst T, Sheppard L, Gifford C, Buchbinder D, Joshi A, Ifversen M, Kleiner GI, Bussel JB, Chandrakasan S, Pesek RD, Pozos TC, Rose MJ, Scurlock AM, Zhang K, Bryceson YT, Bleesing J, Marsh RA.

J Allergy Clin Immunol. 2018 Jul;142(1):333-335.e8. doi: 10.1016/j.jaci.2018.04.017. Epub 2018 May 3. No abstract available.

PMID:
29729304
17.

Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy.

Fassel H, Bussel JB, Roberts SS, Modak S.

J Pediatr Hematol Oncol. 2019 May;41(4):e257-e259. doi: 10.1097/MPH.0000000000001187.

PMID:
29683946
18.

Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.

Grace RF, Despotovic JM, Bennett CM, Bussel JB, Neier M, Neunert C, Crary SE, Pastore YD, Klaassen RJ, Rothman JA, Hege K, Breakey VR, Rose MJ, Shimano KA, Buchanan GR, Geddis A, Haley KM, Lorenzana A, Thompson A, Jeng M, Neufeld EJ, Brown T, Forbes PW, Lambert MP.

Am J Hematol. 2018 Jul;93(7):882-888. doi: 10.1002/ajh.25110. Epub 2018 May 6.

PMID:
29659042
19.

Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment.

Ghanima W, Boiocchi L, Lee CS, Feng X, Geyer JT, Gudbrandsdottir S, Orazi A, Junker P, Bussel JB.

Platelets. 2019;30(2):222-228. doi: 10.1080/09537104.2017.1411586. Epub 2018 Jan 2.

PMID:
29293383
20.

Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia.

Garabet L, Ghanima W, Monceyron Jonassen C, Skov V, Holst R, Mowinckel MC, C Hasselbalch H, A Kruse T, Thomassen M, Liebman H, Bussel JB, Sandset PM.

Platelets. 2019;30(2):206-212. doi: 10.1080/09537104.2017.1394451. Epub 2017 Dec 7.

PMID:
29215956
21.
22.

Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.

Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB.

Blood. 2017 Dec 7;130(23):2527-2536. doi: 10.1182/blood-2017-04-748707. Epub 2017 Oct 17. Erratum in: Blood. 2018 Feb 8;131(6):709.

23.

Fostamatinib for persistent/chronic adult immune thrombocytopenia.

Newland A, Lee EJ, McDonald V, Bussel JB.

Immunotherapy. 2018 Jan;10(1):9-25. doi: 10.2217/imt-2017-0097. Epub 2017 Oct 2. Review.

24.

TPO for ITP in pregnancy.

Bussel JB, Lee EJ.

Blood. 2017 Aug 31;130(9):1073-1074. doi: 10.1182/blood-2017-07-793356. No abstract available.

25.

Imaging and management of fetuses and neonates with alloimmune thrombocytopenia.

Kovanlikaya A, Tiwari P, Bussel JB.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26690. Epub 2017 Jul 4. Review.

PMID:
28675682
26.

Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia.

Kuter DJ, Konkle BA, Hamza TH, Uhl L, Assmann SF, Kiss JE, Kaufman RM, Key NS, Sachais BS, Hess JR, Ness P, McCrae KR, Leissinger C, Strauss RG, McFarland JG, Neufeld E, Bussel JB, Ortel TL.

Am J Hematol. 2017 Aug;92(8):730-738. doi: 10.1002/ajh.24759. Epub 2017 Apr 26.

27.

Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases.

Tsang HC, Bussel JB, Mathew S, Liu YC, Imahiyerobo AA, Orazi A, Geyer JT.

Mod Pathol. 2017 Apr;30(4):486-498. doi: 10.1038/modpathol.2016.218. Epub 2017 Jan 6.

28.

Immune thrombocytopenia: a need for assisted suicide.

Bussel JB, Cooper N.

Br J Haematol. 2017 Jan;176(2):154. doi: 10.1111/bjh.14435. Epub 2016 Nov 23. No abstract available.

PMID:
27879988
29.

Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia.

Liebman HA, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA, Goldenberg DM.

Haematologica. 2016 Nov;101(11):1327-1332. Epub 2016 Aug 11.

30.

Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia.

Lakkaraja M, Jin JC, Manotas KC, Vinograd CA, Ferd P, Gabor J, Wissert M, Berkowitz RL, McFarland JG, Bussel JB.

Transfusion. 2016 Oct;56(10):2449-2454. doi: 10.1111/trf.13779. Epub 2016 Sep 9.

PMID:
27611703
31.

Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia.

Chapin J, Lee CS, Zhang H, Zehnder JL, Bussel JB.

Am J Hematol. 2016 Sep;91(9):907-11. doi: 10.1002/ajh.24434. Epub 2016 Jun 20.

32.

Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia.

Lakkaraja M, Berkowitz RL, Vinograd CA, Manotas KC, Jin JC, Ferd P, Gabor J, Wissert M, McFarland JG, Bussel JB.

Am J Obstet Gynecol. 2016 Oct;215(4):471.e1-9. doi: 10.1016/j.ajog.2016.04.033. Epub 2016 Apr 27.

PMID:
27131591
33.

Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.

Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.

Lancet. 2016 Jul 2;388(10039):45-54. doi: 10.1016/S0140-6736(16)00279-8. Epub 2016 Apr 18.

PMID:
27103127
34.

Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation.

Kucine N, Viny AD, Rampal R, Berger M, Socci N, Viale A, Bussel JB, Levine RL, Rapaport F.

Haematologica. 2016 Jun;101(6):e237-9. doi: 10.3324/haematol.2016.142935. Epub 2016 Mar 18. No abstract available.

35.

What do we know about intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia?

Bussel JB.

Transfusion. 2016 Jan;56(1):17-8. doi: 10.1111/trf.13412. No abstract available.

PMID:
26756707
36.

Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.

Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK.

Lancet Haematol. 2015 Aug;2(8):e315-25. doi: 10.1016/S2352-3026(15)00114-3. Epub 2015 Jul 28. Erratum in: Lancet Haematol. 2015 Oct;2(10):e407.

PMID:
26688484
37.

Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim.

Bussel JB, Wang X, Lopez A, Eisen M.

Hematology. 2016 May;21(4):257-62. doi: 10.1179/1607845415Y.0000000041. Epub 2015 Aug 7.

PMID:
26251926
38.

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.

Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK.

Lancet. 2015 Oct 24;386(10004):1649-58. doi: 10.1016/S0140-6736(15)61107-2. Epub 2015 Jul 28. Erratum in: Lancet. 2015 Oct 24;386(10004):1630.

PMID:
26231455
39.

Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.

Gerrits AJ, Leven EA, Frelinger AL 3rd, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB.

Blood. 2015 Sep 10;126(11):1367-78. doi: 10.1182/blood-2014-09-602573. Epub 2015 Jul 29.

40.

Suppression of in vitro megakaryopoiesis by maternal sera containing anti-HPA-1a antibodies.

Liu ZJ, Bussel JB, Lakkaraja M, Ferrer-Marin F, Ghevaert C, Feldman HA, McFarland JG, Chavda C, Sola-Visner M.

Blood. 2015 Sep 3;126(10):1234-6. doi: 10.1182/blood-2014-11-611020. Epub 2015 Jul 24.

41.

Collaborating to support Healthy Kids, Healthy Communities partnerships.

Strunk SL, Brennan LK, Bors PA, Bussel JB, Eng E, Leonard BA.

J Public Health Manag Pract. 2015 May-Jun;21 Suppl 3:S8-15. doi: 10.1097/PHH.0000000000000187.

PMID:
25828227
42.

The Healthy Kids, Healthy Communities national program.

Strunk SL, Bussel JB.

J Public Health Manag Pract. 2015 May-Jun;21 Suppl 3:S1-3. doi: 10.1097/PHH.0000000000000188.

PMID:
25828210
43.

Review of fetal and neonatal immune cytopenias.

Lewin S, Bussel JB.

Clin Adv Hematol Oncol. 2015 Jan;13(1):35-43. Review.

PMID:
25679972
44.

Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).

Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, Ho RH, Nie K, Eisen M.

Pediatr Blood Cancer. 2015 Feb;62(2):208-213. doi: 10.1002/pbc.25136. Epub 2014 Oct 24.

45.

Thrombopoietin receptor agonists: a critical review.

Mitchell WB, Bussel JB.

Semin Hematol. 2015 Jan;52(1):46-52. doi: 10.1053/j.seminhematol.2014.11.001. Epub 2014 Nov 7. Review.

PMID:
25578419
46.

The new thrombopoietic agenda: impact on leukemias and MDS.

Bussel JB.

Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):288-92. doi: 10.1016/j.beha.2014.10.012. Epub 2014 Oct 15. Review.

PMID:
25455280
47.

IRAK-4 and MyD88 deficiencies impair IgM responses against T-independent bacterial antigens.

Maglione PJ, Simchoni N, Black S, Radigan L, Overbey JR, Bagiella E, Bussel JB, Bossuyt X, Casanova JL, Meyts I, Cerutti A, Picard C, Cunningham-Rundles C.

Blood. 2014 Dec 4;124(24):3561-71. doi: 10.1182/blood-2014-07-587824. Epub 2014 Oct 15.

48.

Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.

Mitchell WB, Pinheiro MP, Boulad N, Kaplan D, Edison MN, Psaila B, Karpoff M, White MJ, Josefsson EC, Kile BT, Bussel JB.

Am J Hematol. 2014 Dec;89(12):E228-34. doi: 10.1002/ajh.23832. Epub 2014 Sep 2.

49.

A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?

LeVine DN, Birkenheuer AJ, Brooks MB, Nordone SK, Bellinger DA, Jones SL, Fischer TH, Oglesbee SE, Frey K, Brinson NS, Peters AP, Marr HS, Motsinger-Reif A, Gudbrandsdottir S, Bussel JB, Key NS.

Br J Haematol. 2014 Oct;167(1):110-20. doi: 10.1111/bjh.13005. Epub 2014 Jul 8.

50.

Management of thrombocytopenia.

Izak M, Bussel JB.

F1000Prime Rep. 2014 Jun 2;6:45. doi: 10.12703/P6-45. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center